Biomedical Engineering — US PTAB Patent Cases
3 decisions indexed
Page 1 of 1 · 3 total
Axion Biosystems, Inc. v.Agilent Technologies, Inc.
Axion Biosystems successfully navigated the Institution Decision phase in its IPR against Agilent Technologies, leading to the trial of key claims. The Board declined to deny institution, allowing the dispute over cell monitoring and impedance analysis technology to proceed to litigation.
Embody, Inc. et al. v.LifeNet Health
Embody and Zimmer Biomet successfully secured institution in this IPR against LifeNet Health's '223 patent. The Board found a reasonable likelihood that claims related to collagen scaffolds with specific FFT analysis characteristics are unpatentable over prior art references like Huang2 and Lee.
Embody, Inc. et al. v.LifeNet Health
Embody, Inc. challenged LifeNet Health's tissue engineering patent (11318227) based on anticipation and obviousness. The PTAB instituted trial on all eight claims after finding merit in the petitioner’s arguments regarding fiber alignment and FFT analysis.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.